Analyst Price Target is $33.20
▼ -0.93% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Recursion Pharmaceuticals in the last 3 months. The average price target is $33.20, with a high forecast of $36.00 and a low forecast of $31.00. The average price target represents a -0.93% upside from the last price of $33.51.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Recursion Pharmaceuticals.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.